ZURICH (Reuters) - Roche Holding AG's Herceptin combined with Pertuzumab showed "impressive results" in a Phase II breast cancer trial, the Swiss drugmaker said on Friday.

NEW YORK (Reuters) - Pfizer Inc said on Tuesday it was halting a late stage study of its experimental drug for advanced melanoma after a review of interim data showed it was no better than standard chemotherapy.

Amid safety concerns, AstraZeneca has stopped a trial of an experimental medicine to treat lung cancer

WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new drug to be sold by Regeneron Pharmaceuticals Inc to treat certain chronic but rare inherited inflammatory disorders.

LONDON (Reuters) - The pharmaceutical market is failing to conceive of new pregnancy medication, creating just three drug patents for maternal health in 28 years, British researchers said on Tuesday.

BOSTON (Reuters) - Nearly a third of antidepressant drug studies are never published in the medical literature and nearly all happen to show that the drug being tested did not work, researchers reported on Wednesday.

NEW YORK (Reuters Health) - Ziprasidone, sold under the trade name Geodon, is well tolerated by patients and shows long-term efficacy as maintenance therapy for patients with schizophrenia who have not responded to other drugs, according to the results of a clinical trial published in the Journal of Clinical Psychiatry.

PARIS (Reuters) - French pharmaceuticals group Sanofi-Aventis said on Wednesday that data showed improvements in work performance in patients with chronic insomnia treated with its blockbuster Ambien drug .

· Side effects of pill will be avoided, say researchers· Suppository or skin patch product still 10 years away

WASHINGTON (Reuters) - A new chemotherapy drug called Ixempra made by Bristol-Myers Squibb Co for women with advanced breast cancer that does not respond to other therapies has won U.S. approval to be sold and is expected to be available in days.